Aurobindo Pharma Limited will host an analyst and investor call on August 6, 2026, at 8:30 AM IST to discuss its unaudited financial results for the first quarter ended June 30, 2026. The event provides stakeholders with an opportunity to review the company’s performance in Q1FY27 and address queries regarding operational and financial outcomes. This disclosure ensures timely access to material information for investors and market participants following the release of quarterly earnings.

The announcement was made pursuant to Regulation 30(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company submitted the schedule to the Listing Department of the National Stock Exchange of India Limited and the Corporate Relations Department of BSE Limited. B. Adi Reddy, Company Secretary, digitally signed the communication on July 29, 2026.

Call Details

Participants can join the earnings call through Zoom by pre-registering via the provided link or accessing the session directly through the browser. The earnings presentation will be available on the company’s website after the results announcement.

Regulatory Compliance

The notice was issued to ensure compliance with listing obligations under SEBI regulations. The company code for Aurobindo Pharma Limited is AUROPHARMA on NSE and 524804 on BSE. The corporate office is located in Hyderabad Knowledge City, Ranga Reddy District, Telangana, while the registered office is situated in Ameerpet, Hyderabad.

What This Means for Investors

The earnings call serves as a critical channel for management to contextualize the Q1FY27 financial data. Investors should note that the discussion will focus on unaudited figures, which may be subject to revision upon final audit. The availability of the presentation post-call allows for detailed analysis of segment performance and key metrics disclosed during the quarter.

Aurobindo Pharma has signed a non-exclusive, royalty-free voluntary licensing agreement with MSD (trade name of Merck & Co., Inc.) to supply generic alimtravir to 129 low- and middle-income countries (LMICs). Announced on July 24, 2026, the deal enables the company to manufacture the drug, which targets regions accounting for the majority of new HIV diagnoses globally. This early execution, occurring before the completion of Phase 3 trial enrollment, marks a first in HIV prevention, allowing stakeholders to plan for scale-up operations immediately upon regulatory approval.

The agreement is subject to applicable regulatory approvals and requirements. Aurobindo Pharma joins a select group of global generic manufacturers in signing such agreements, aiming to meet internationally recognized standards once regulatory hurdles are cleared. The company’s corporate office is located in Hyderabad, Telangana.

Key Deal Parameters

The following table outlines the core terms of the licensing agreement between Aurobindo Pharma and MSD:

Leadership Perspectives

Umesh K, Associate President & Head – Global Access & Licensing at Aurobindo Pharma, stated that expanding access to high-quality, affordable medicines remains central to the company's purpose. He noted that the collaboration reflects a commitment to partnering with innovators to accelerate equitable access to potential new therapies. The goal is to make alimtravir available across eligible LMICs, helping strengthen global efforts towards HIV prevention.

Gregg Szabo, Senior Vice President, Global HIV Marketing at MSD, expressed pleasure in working with Aurobindo and other manufacturers involved in these voluntary licensing agreements. He emphasized that this early action will help stakeholders across the HIV response plan for the scale-up needed to reach people who could benefit from HIV prevention, following necessary regulatory approvals.

Strategic Significance

The focus on 129 LMICs highlights a strategic concentration on markets that account for the majority of new HIV diagnoses globally. By securing rights before Phase 3 trials conclude, Aurobindo Pharma positions itself to move rapidly upon approval, bypassing typical post-approval licensing delays. This proactive approach underscores the importance of speed-to-market in public health interventions, particularly for preventive therapies in resource-constrained settings.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE406A01037/22ca7b243fd94d73.pdf